Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
EYEN Eyenovia Inc
- Stocks
- Healthcare
- NASDAQ: EYEN
Price (delayed)
$2.08
Market cap
$6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$44.6
Enterprise value
$13.21M
Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for
Highlights
Eyenovia's debt has decreased by 33% YoY
The company's equity rose by 26% QoQ
The company's gross margin has shrunk by 128% YoY but it rose by 19% QoQ
The company's quick ratio has surged by 100% QoQ but it fell by 47% YoY
Key stats
What are the main financial stats of EYEN
Market
Valuations
Earnings
Shares outstanding
2.88M
Market cap
$6M
Enterprise value
$13.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
67.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
196.95
Revenue
$67,063
Gross profit
-$3.66M
Operating income
-$41.5M
Net income
-$42.38M
EBIT
-$39.99M
EBITDA
-$39.04M
Free cash flow
-$24.72M
Per share
Balance sheet
Liquidity
EPS
-$44.6
EPS diluted
-$44.6
Free cash flow per share
-$11.29
Book value per share
-$8.99
Revenue per share
$0.03
TBVPS
$2.73
Total assets
$5.98M
Total liabilities
$15.7M
Debt
$11.15M
Equity
-$9.71M
Working capital
-$9.94M
Debt to equity
-1.15
Current ratio
0.34
Quick ratio
0.26
Net debt/EBITDA
-0.18
Margins
Efficiency
Dividend
EBITDA margin
-58,208.4%
Gross margin
-5,453.4%
Net margin
-63,194.1%
Operating margin
-61,885.2%
Return on assets
-329.5%
Return on equity
N/A
Return on invested capital
-1,340.4%
Return on capital employed
N/A
Return on sales
-59,634.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EYEN stock price
How has the Eyenovia stock price performed over time
Intraday
-1.42%
1 week
24.55%
1 month
77.78%
1 year
-96.47%
YTD
-82.19%
QTD
89.09%
Financial performance
How have Eyenovia's revenue and profit performed over time
Revenue
$67,063
Gross profit
-$3.66M
Operating income
-$41.5M
Net income
-$42.38M
Gross margin
-5,453.4%
Net margin
-63,194.1%
The company's gross margin has shrunk by 128% YoY but it rose by 19% QoQ
Eyenovia's net margin has soared by 83% YoY and by 27% from the previous quarter
The operating margin has soared by 82% YoY and by 27% QoQ
EYEN's operating income is down by 37% YoY but it is up by 15% from the previous quarter
Price vs fundamentals
How does EYEN's price correlate with its fundamentals
Growth
What is Eyenovia's growth rate over time
Valuation
What is Eyenovia stock price valuation
P/E
N/A
P/B
N/A
P/S
67.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
196.95
The EPS has grown by 25% from the previous quarter and by 25% YoY
The company's equity rose by 26% QoQ
The P/S is 88% below the last 4 quarters average of 584.8
The revenue is up by 17% since the previous quarter
Efficiency
How efficient is Eyenovia business performance
Eyenovia's ROIC has plunged by 85% from the previous quarter
The ROS has soared by 82% YoY and by 28% from the previous quarter
Eyenovia's ROA has decreased by 18% from the previous quarter
Dividends
What is EYEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EYEN.
Financial health
How did Eyenovia financials performed over time
The total assets is 62% smaller than the total liabilities
The company's quick ratio has surged by 100% QoQ but it fell by 47% YoY
Eyenovia's current ratio has soared by 100% from the previous quarter but it has plunged by 61% YoY
Eyenovia's debt to equity has shrunk by 113% YoY and by 34% QoQ
Eyenovia's debt has decreased by 33% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.